Macrophage therapy for liver cirrhosis
| ISRCTN | ISRCTN10368050 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10368050 |
| EudraCT/CTIS number | 2015-000963-15 |
| Secondary identifying numbers | MR/M007588/1 |
- Submission date
- 29/06/2016
- Registration date
- 04/07/2016
- Last edited
- 14/01/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Plain English Summary
Background and study aims
Liver disease can overtime cause scarring and damage to the liver and eventually lead to a condition called liver cirrhosis. When this happens the liver is unable to work properly and the person can become tired and unwell. A malfunctioning liver makes people prone to infection, bruising, swelling, confusion and jaundice (yellowing of the skin). Cirrhosis is the fifth most common cause of death in UK. Currently we have no cure for liver cirrhosis but liver transplant. This is a very big operation which requires lifelong treatment with immunosuppressant drugs. Not everyone is suitable to have a liver transplant and there aren’t enough transplantable livers to cure all the patients. Our group has demonstrated using animals models that selected cells (monocytes) taken from the patient’s own blood can be grown in the laboratory into cells called macrophages and infused back into the patient to replace damaged liver cells. The aim of this study is to test the safety and effectiveness of autologous macrophage infusion in humans.
Who can participate?
Adults age 16-75 with liver cirrhosis
What does the study involve?
The first part of the study is to check that the macrophages are safe and find out the best number of macrophages to use. Three patients receive the same dose and if there are no side effects the dose is increased for the second group of three patients, until the maximum safe dose is reached. The second part of the study looks at whether the treatment can benefit patients with liver disease. Patients are randomly allocated to receive either the macrophage treatment or standard medical care. Liver function is then assessed after 3 months.
What are the possible benefits and risks of participating?
Patients may not gain direct benefit from the study but this could lead to the development in the future of a treatment for liver cirrhosis. This is a first in human study so the side effects are not known. We could potentially witness side effects similar to blood transfusion reactions or allergic reactions. Macrophages Activation Syndrome is a very rare condition that could potential arise from this treatment. This will be characterised by low blood pressure and difficulties in breathing. Appropriate measures are in place in the remote eventuality this may occur. Liver function could worsen. There is no information available to support the increased risk of cancer but it is difficult to predict. Patients could experience discomfort during blood sampling.
Where is the study run from?
Edinburgh Royal Infirmary (UK)
When is the study starting and how long is it expected to run for?
August 2016 to August 2021
Who is funding the study?
Medical Research Council (UK)
Who is the main contact?
Prof. Stuart Forbes
Stuart.Forbes@ed.ac.uk
Contact information
Scientific
SCRM Building
University of Edinburgh
5 Little France Drive
Edinburgh
EH16 4UU
United Kingdom
| Phone | +44 (0)131 651 9510 |
|---|---|
| fmoroni@ed.ac.uk |
Study information
| Study design | Dose-escalation phase I single-centre study with 3+3 design followed by randomized controlled single-centre phase II study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a participant information sheet |
| Scientific title | Macrophage therapy for liver cirrhosis |
| Study acronym | MATCH01 |
| Study hypothesis | Autologous macrophages therapy can improve liver function and reduce fibrosis in patients with established liver cirrhosis. |
| Ethics approval(s) | REC - Research Ethics Committee South East Scotland, 24/06/2016, REC ref: 15/SS/0121 |
| Condition | Liver cirrhosis |
| Intervention | Dose-escalation phase I single-centre study with 3+3 design: 3 patients will receive the same dose, if no dose-limiting toxicity recorded dose will be escalated to the second group of 3 patients until maximum tolerated dose. Followed by randomised controlled single centre phase II study of autologous activated macrophage infusion versus standard medical care. Macrophages will be infused via peripheral vein for the duration of 30 minutes. Participants will be randomised 1:1 via computer system based on a minimisation algorithm using the key variable aetiology of disease. No blinding will be possible but efficacy data will be analysed at the end of the trail to avoid bias. |
| Intervention type | Biological/Vaccine |
| Pharmaceutical study type(s) | Not Applicable |
| Phase | Phase I/II |
| Drug / device / biological / vaccine name(s) | Autologous activated macrophage infusion |
| Primary outcome measure | Phase I: The safety and feasibility of re-infusion of autologous macrophages, measured 14 days after infusion of 3rd patient in each dose escalation group (model 3+3), and the maximum safe dose of infusion Phase II: Liver function (MELD score) at 3 months |
| Secondary outcome measures | 1. Markers of liver fibrosis 2. Disease-related quality of life 3. Liver-related clinical events 4. Transplant-free survival Measured at 3 months and 1 year (improvement in markers of fibrosis of the liver, improvement of quality of life, transplant free) |
| Overall study start date | 01/08/2016 |
| Overall study end date | 01/08/2021 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 55-74 |
| Total final enrolment | 63 |
| Participant inclusion criteria | 1. Age 17-65 2. Liver cirrhosis 3. Model for End-Stage Liver Disease (MELD) score 10-16 4. Aetiology liver disease: ALRD, NAFLD, PBC, hemochromatosis, alpha 1 anti trypsin deficiency, previous Hep C with SVR |
| Participant exclusion criteria | 1. Refusal or inability to give informed consent to participate in the study 2. Other cause of chronic liver disease/cirrhosis not included in listed aetiologies – this is left to the clinical judgement of the investigator based on previous investigations and trial screening 3. Portal hypertensive bleeding; active episode of bleeding requiring hospitalisation in the last 3 months where varices have not been eradicated by banding 4. Ascites unless, in the opinion of the investigator, the ascites is minimal and well controlled with no increase to diuretic therapy in last 3 months 5. Encephalopathy; current or requiring hospitalisation for treatment in last 3 months 6. Hepatocellular carcinoma – uncertain cases to be discussed at local hepatobiliary multidisciplinary meeting, dysplastic or indeterminate nodules to be excluded, regenerative or other nodules to be included at discretion of MDM 7. Previous diagnosis of hepatocellular carcinoma 8. Previous organ transplant or previous recipient of tissue 9. Listed for liver transplantation 10. Any situation that in the Investigators' opinion may interfere with optimal study participation such as alcohol or drug abuse, domicile too distant from study site, potential non-compliance or inability to co-operate 11. Presence of clinically relevant acute illness that in the opinion of the investigator might compromise the participant’s safe participation in the study 12. Presence or history of cancer within past 5 years with exception of adequately treated localised skin carcinoma, in situ cervical cancer or solid malignancy surgically excised in total without recurrence for 5 years 13. Pregnancy or breastfeeding |
| Recruitment start date | 01/08/2016 |
| Recruitment end date | 26/11/2021 |
Locations
Countries of recruitment
- Scotland
- United Kingdom
Study participating centres
Edinburgh
EH16 4SA
United Kingdom
Dundee
DD1 9SY
United Kingdom
Glasgow
G4 0SF
United Kingdom
Sponsor information
University/education
Research Governance & QA Office
Queens Medical Research Institute
47 Little France Crescent
Edinburgh
EH16 4TJ
Scotland
United Kingdom
| Phone | +44 (0)131 242 9418 |
|---|---|
| fiach.o'mahony@ed.ac.uk | |
| Website | http://accord.scot/ |
"ROR" |
https://ror.org/01x6s1m65 |
Funders
Funder type
Research council
Government organisation / National government
- Alternative name(s)
- Medical Research Council (United Kingdom), UK Medical Research Council, MRC
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 01/08/2023 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Phase I primary safety results | 01/10/2019 | 10/10/2019 | Yes | No |
| Protocol article | 08/11/2021 | 10/11/2021 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No | ||
| Results article | Primary and secondary clinical outcomes | 10/01/2025 | 14/01/2025 | Yes | No |
Editorial Notes
14/01/2025: Publication reference added.
19/10/2022: The following changes were made:
1. The target number of participants was changed from 65-74 to 55-74.
2. The total final enrolment was added.
3. The recruitment end date has been changed from 01/08/2020 to 26/11/2021.
4. Ninewells Hospital and Glasgow Royal Infirmary have been added as centres.
5. The intention to publish date has been changed from 01/08/2022 to 01/08/2023.
10/11/2021: Publication reference added.
10/10/2019: Publication reference added.
01/03/2019: Internal review.
01/11/2017: Internal review.
05/07/2016: Internal review.
